INTRODUCTION {#S0001}
============

Intense exercise involving eccentric contractions induces skeletal muscle damage including reactive nitrogen/oxygen species (RN/OS) generation, which represents an important mechanism in the adaptation to physical work. Nitric oxide (NO) and hydrogen peroxide (H~2~O~2~), as cellular mediators in signal transmission, can activate transcription factors e.g. hypoxia-inducible factor-1 (HIF-1) \[[@CIT0006], [@CIT0010], [@CIT0017], [@CIT0022]\]. HIF-1 is an essential binding element in the 3' enhancer of the EPO gene, and its activity can be regulated by several different mechanisms including oxygen-dependent pathways and oxygen-independent factors such as sirtuins, protein kinases, microRNAs and RN/OS. The mechanism by which RN/OS acts on HIF-1 and EPO-gene expression is controversially discussed. Fandrey et al. \[[@CIT0010]\] demonstrated that the low endogenous H~2~O~2~ production under hypoxic conditions is associated with a high rate of EPO synthesis. In contrast, Chandel et al. \[[@CIT0008]\] reported an increase in H2O2 generation and HIF-1 activity under hypoxic conditions.

Hypoxia is a major regulatory factor for EPO synthesis. However, several chemically diverse antioxidants also can affect HIF-1 activity and EPO expression \[[@CIT0011], [@CIT0015], [@CIT0018], [@CIT0027], [@CIT0031], [@CIT0037], [@CIT0038]\]. α-Lipoic acid is a very interesting antioxidant because of its anti- and pro-oxidative activity. It reduces superoxide and hydroxyl radicals but it can generate H~2~O~2~ via auto-oxidation depending on the time and dose of its administration \[[@CIT0026]\]. In animal studies, it has been shown that α-lipoic acid at doses from 12.5 mg · kg^-1^ to 100 mg · kg^-1^ body weight improved the anti-oxidative response while doses over 100 g · kg^-1^ induced pro-oxidative processes \[[@CIT0007], [@CIT0014]\]. In human studies, α-lipoic acid is used as a dietary supplement at doses from 100 to 1200 mg daily but as a medication it is recommended at high doses (up to 1800 mg · d^-1^) for a long period (up to 6 months) in diabetic neuropathy and other diseases \[[@CIT0002], [@CIT0026]\]. The time and dose of α-lipoic acid supplementation seems to be important for α-lipoic acid activity. In our previous study, 600 mg of α-lipoic acid revealed an antioxidant action but did not improve the haematological response \[[@CIT0036]\]. Freudenthaler et al. \[[@CIT0011]\] used very short-term α-lipoic acid treatment (1200 mg) with an infusion pump (20 mg · min^-1^) during 6 h hypoxia. They did not observe any changes in markers of RN/OS activity or EPO level. Nonetheless, a recent study provided evidence for the use of α-lipoic acid as an EPO adjuvant, reducing the requirement for EPO in patients undergoing haemodialysis \[[@CIT0009]\].

This study was designed to determine whether intake of high-dose α-lipoic acid before running eccentric exercise demonstrates antioxidative activity and enhances EPO release through changes in RN/OS generation.

MATERIALS AND METHODS {#S0002}
=====================

Sixteen healthy males participated in this randomised and placebo-controlled study ([Table 1](#T0001){ref-type="table"}). During the study, subjects were requested to avoid nutritional supplements and physical effort for 48 h before and after the exercise trials. All the subjects were informed of the aim of the study and gave their written consent for participation in the project. The protocol of the study was approved by the local ethics committee in accordance with the Helsinki Declaration.

###### 

ANTHROPOMETRIC AND BODY COMPOSITION DATA IN SUBJECTS (MEAN ± SD)

                   α-Lipoic acid n = 8   Placebo n = 8   P-value
  ---------------- --------------------- --------------- ---------
  Age (yr)         20.5 ± 0.1            20.9 ± 0.8      0.414
  Height (cm)      183.1 ± 4.1           175.6 ± 7.1     0.072
  Weight (kg)      74.1 ± 4.0            72.5 ± 7.7      0.677
  BMI (kg·m^-2^)   22.2 ± 1.0            23.3 ± 1.2      0.139
  FM (kg)          12.9 ± 1.7            14.8 ± 3.5      0.235
  FM (%)           17.5 ± 2.0            20.1 ± 3.4      0.105
  FFM (kg)         61.1 ± 3.5            58.2 ± 5.4      0.343
  FFM (%)          82.5 ± 2.0            79.9 ± 3.4      0.105

Note: BMI -- body mass index; FFM -- fat-free mass; FM -- fat mass

The maximal oxygen uptake (VO~2~max) was determined on a treadmill Trackmaster TM310 (USA) at the temperature of 22°C and the relative air humidity of 60%. Breath-by-breath oxygen uptake was continuously recorded using the Oxycon Mobile ergospirometric system (Viasys Healthcare Inc., USA). Heart rate was continuously recorded during the test using a portable heart rate telemetry device: Polar Sport Tester T61 (Finland). The test was incremental and progressive; all subjects commenced at a 4.5 mph running speed and it was increased by 0.5 mph every 2 min until the maximal level of recorded parameters was achieved. The VO~2~max was determined between 8 a.m. and 2 p.m. a week before the beginning of the experiment.

The subjects were assigned to one of two groups: placebo and α-lipoic acid (Thiogamma 600 Wörwag Pharma; 2 × 600 mg · d^-1^ for 10 days prior to the exercise trial). The exercise trial involved a 90 min run at 65% VO~2~max (0% gradient) followed by a 15-min eccentric phase (-10% gradient) at 65% VO~2~max. Blood samples were obtained from the antecubital vein using S-Monovette tubes (Sarstedt, Austria) at pre-exercise and post-exercise periods (20 min, 24 h and 48 h). Within 20 min, blood samples were centrifuged at 3000 g and 4°C for 10 min. Serum for markers of RN/OS activity, EPO and CK was stored at -80°C.

Reactive nitrogen/oxygen species (RN/OS) {#S20003}
----------------------------------------

Serum nitric oxide (NO) and hydroperoxide (H~2~O~2~) concentrations were determined using Oxis Research kit (USA). NO and H~2~O~2~ were measured immediately after serum collection, on the day of exercise study. NO and H~2~O~2~ detection limits were 0.5 nmol · mL^-1^ and 6.25 nmol · mL^-1^, respectively. The intra-assay coefficient of variation (CV) for the NO kit and the H~2~O~2~ kit was \<10%.

Markers of RN/OS activity {#S20004}
-------------------------

Serum 8-isoprostanes (8-iso) were measured with a Cayman kit (USA). The 8-Iso detection limit for the procedure was 2.7 pg · mL^-1^, and the intra-assay coefficient of variation (CV) was 6.4%. Lipid peroxide (LPO) and protein carbonyl (PC) concentrations were determined using the Oxis Research kit (USA) and Alexis Biochemicals kit (USA). The detection limits for LPO and PC were 0.1 nmol · mL^-1^. The intra-assay coefficients of variation (CV) for LPO and PC kits were \<10%.

Erythropoietin {#S20005}
--------------

Serum erythropoietin (EPO) level was determined by the enzyme immunoassay method using a commercial kit from R&D Systems (USA). The EPO detection limit for the applied kit was 0.6 mIU · mL^-1^. The intra-assay CV for the EPO kit was \<8%.

Haematological variables {#S20006}
------------------------

Haemoglobin (HB), haematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC) as well as erythrocyte (RBC) and reticulocyte counts (RET) and reticulocyte relative number (percentage) (RET%) were assessed using Sysmex XE-2100 (Japan) in EDTA blood samples.

Creatine kinase {#S20007}
---------------

Total serum creatine kinase (CK) activity was used as a marker of muscle damage and was evaluated using an Emapol kit (Poland). The CK detection limit for the applied kit was 6 IU · L^-1^. The intra-assay CV for the CK kit was 1.85%.

Statistical analysis {#S20008}
--------------------

A two-way analysis of variance (ANOVA) with repeated measures was used to determine the effect of exercise and α-lipoic acid on analysed parameters \[(pre-exercise vs. post-exercise) × (placebo vs. α-lipoic acid)\]. Tukey\'s post-hoc test was used to determine differences between group means. The relationships between variables were determined using Pearson\'s correlation and linear regression. All results are expressed as mean and standard deviation (x ± SD). Statistical significance was set at *P*\<0.05. Statistical analysis was carried out using Statistica 10 and the statistical package R2.10.0 (R Development Core Team 2009).

RESULTS {#S0003}
=======

Reactive nitrogen/oxygen species {#S20010}
--------------------------------

The running eccentric exercise caused a significant increase in NO and H~2~O~2~ concentrations. Changes in H~2~O~2~ already occurred at 20 min after exercise and were higher than changes in NO generation. The H~2~O~2~ level was still elevated (*P*\<0.001) at 48 h after exercise. ANOVA showed a significant interaction between α-lipoic acid and exercise. α-Lipoic acid intake increased H~2~O~2~ concentration 2-fold at pre-exercise but reduced changes in H~2~O~2~ and NO during recovery. Changes in NO/H~2~O~2~ ratio were mainly dependent on H~2~O~2~ level. α-Lipoic acid reduced the NO/H~2~O~2~ ratio 2-fold at pre-exercise, 20 min and 24 h, but elevated it at 48 h after exercise ([Table 2](#T0002){ref-type="table"}).

###### 

SELECTED NITRO-OXIDATIVE STRESS MARKERS IN α-LIPOIC ACID (N = 8) AND PLACEBO (N = 8) GROUPS (MEAN ± SD)

                        Pre-exercise (after 10-d placebo or α-lipoic acid intake)   Post-exercise 20 min   Post-exercise 24 h   Post-exercise 48 h   *P*-value [\*](#TF0001){ref-type="table-fn"}
  --------------------- ----------------------------------------------------------- ---------------------- -------------------- -------------------- ----------------------------------------------
  NO nmol·mL^-1^                                                                                                                                     
   α-lipoic acid        26.64 ± 4.96                                                31.67 ± 7.35           34.37 ± 8.77         30.33 ± 7.56         0.215
   Placebo              32.99 ± 4.76                                                35.08 ± 5.45           45.65 ± 5.58         35.88 ± 4.91         \<0.001
  H~2~O~2~nmol·mL^-1^                                                                                                                                
   α-lipoic acid        25.01 ± 2.21                                                22.05 ± 4.97           25.73 ± 2.72         17.04 ± 1.84         \<0.001
   Placebo              13.71 ± 3.39                                                30.26 ± 4.37           20.99 ± 3.42         26.28 ± 2.61         \<0.001
  NO/H~2~O~2~                                                                                                                                        
   α-lipoic acid        1.07 ± 0.24                                                 1.52 ± 0.55            1.35 ± 0.36          1.80 ± 0.50          \<0.001
   Placebo              2.57 ± 0.87                                                 1.19 ± 0.28            2.24 ± 0.55          1.38 ± 0.21          \<0.001
  8-iso pg·mL^-1^                                                                                                                                    
   α-lipoic acid        18.43 ± 3.90                                                31.92 ± 8.31           17.83 ± 5.83         16.67 ± 3.85         0.479
   Placebo              24.38 ± 8.40                                                40.92 ± 6.32           22.00 ± 6.68         27.68 ± 8.29         \<0.001
  LPO nmol·mg^-1^                                                                                                                                    
   α-lipoic acid        1.75 ± 0.56                                                 2.22 ± 0.38            2.04 ± 0.61          1.77 ± 0.57          0.275
   Placebo              1.37 ± 0.42                                                 2.50 ± 0.58            2.16 ± 0.71          1.55 ± 0.26          \<0.001
  PC nmol·mg^-1^                                                                                                                                     
   α-lipoic acid        5.20 ± 0.95                                                 6.66 ± 1.33            6.65 ± 1.54          6.87 ± 1.05          \<0.05
   Placebo              4.60 ± 0.77                                                 6.78 ± 1.43            7.40 ± 1.88          5.67 ± 1.62          \<0.05

Note: The first *P*-value for each variable is the group x time interaction effect, and the second is the time effect.

Abbreviations: NO nitric oxide, H~2~O~2~ hydrogen peroxide, 8-isoprostanes, LPO lipid peroxides, PC protein carbonyls

Markers of RN/OS activity {#S20011}
-------------------------

The running eccentric exercise significantly elevated 8-iso, LPO and PC concentrations at 20 min and 24 h after exercise. α-Lipoic acid prevented post-exercise changes in 8-iso, LPO and PC levels; thus it revealed antioxidative activity. However, there were no significant differences in LPO and PC between placebo and α-lipoic acid ([Table 2](#T0002){ref-type="table"}).

Erythropoietin {#S20012}
--------------

The exercise trial significantly increased EPO concentration at 20 min post-exercise. α-Lipoic acid enhanced EPO production both before exercise and during recovery. EPO level was especially high at 48 h after exercise. Interestingly, EPO did not correlate with NO and H~2~O~2~ separately but correlated with NO/H~2~O~2~ ratio in the α-lipoic acid group ([Figure 1](#F0001){ref-type="fig"}). EPO also correlated with total CK activity (r = 0.478, *P*\<0.01), which reached a peak at 24 h after exercise ([Figure 2](#F0002){ref-type="fig"}). This means that changes in RN/OS generation and muscle damage are important factors affecting EPO release.

![THE RELATION OF ERYTHROPOIETIN (EPO) LEVEL WITH NITRIC OXIDE AND HYDROGEN PEROXIDE RATIO (NO/H~2~O~2~) FOLLOWING EXERCISE TRIAL IN α-LIPOIC ACID GROUP (N = 8)\
Note: r = 0.718, *P*\<0.01](JBS-31-1111435-g001){#F0001}

![THE RELATION OF ERYTHROPOIETIN (EPO) LEVEL TO TOTAL CREATINE KINASE (CK) ACTIVITY FOLLOWING EXERCISE TRIAL IN α-LIPOIC ACID GROUP (N = 8)\
Note: r = 0.478, P \< 0.01.](JBS-31-1111435-g002){#F0002}

Haematological variables {#S20013}
------------------------

HB concentration did not change following exercise but it was significantly elevated after α-lipoic acid at pre-exercise, 20 min, and 24 h post-exercise. Other haematological variables did not change after either exercise and α-lipoic acid; however, RBC and RET numbers as well as MCV tended to high values after α-lipoic acid intake ([Table 3](#T0003){ref-type="table"}).

###### 

ERYTHROPOIETIN AND HAEMATOLOGICAL VARIABLES IN α-LIPOIC ACID (N = 8) AND PLACEBO (N = 8) GROUPS (MEAN ± SD)

                     Pre-exercise (after 10-d placebo or α-lipoic acid intake)   Post-exercise 20 min   Post-exercise 24 h   Post-exercise 48 h   P-value [\*](#TF0002){ref-type="table-fn"}
  ------------------ ----------------------------------------------------------- ---------------------- -------------------- -------------------- --------------------------------------------
  EPO (mIU·mL^-1^)                                                                                                                                
   α-lipoic acid     12.36 ± 2.50                                                16.51 ± 5.52           19.63 ± 10.25        23.90 ± 11.24        0.154
   placebo           7.22 ± 1.31                                                 13.41 ± 4.89           10.95 ± 4.85         10.71 ± 5.16         \<0.01
  HB (g·dL^-1^)                                                                                                                                   
   α-lipoic acid     16.00 ± 0.45                                                16.09 ± 0.45           15.64 ± 0.82         15.23 ± 0.71         0.457
   placebo           14.60 ± 0.53                                                15.26 ± 0.77           14.50 ± 0.84         14.59 ± 0.67         \<0.05
  RBC (mln·mm^-3^)                                                                                                                                
   α-lipoic acid     5.42 ± 0.26                                                 5.44 ± 0.22            5.32 ± 0.13          5.17 ± 0.16          0.708
   placebo           5.17 ± 0.18                                                 5.14 ± 0.20            5.01 ± 0.26          5.03 ± 0.27          \>0.05
  HCT (%)                                                                                                                                         
   α-lipoic acid     47.70 ± 1.12                                                47.38 ± 1.23           47.10 ± 1.47         45.74 ± 1.76         0.627
   placebo           45.00 ± 1.49                                                44.69 ± 1.91           43.46 ± 1.94         43.69 ± 1.66         \<0.05
  RET (%)                                                                                                                                         
   α-lipoic acid     7.75 ± 1.39                                                 7.63 ± 1.49            7.88 ± 1.36          6.38 ± 1.22          0.081
   placebo           5.38 ± 0.86                                                 4.88 ± 0.93            4.88 ± 0.78          5.50 ± 1.00          \>0.05
  MCV (fL)                                                                                                                                        
   α-lipoic acid     89.13 ± 2.21                                                88.69 ± 2.23           88.99 ± 2.37         89.53 ± 1.81         0.998
   placebo           86.29 ± 2.41                                                85.84 ± 2.41           85.89 ± 2.27         86.53 ± 2.07         \>0.05
  MCH (pg·RBC^-1^)                                                                                                                                
   α-lipoic acid     29.87 ± 1.35                                                29.97 ± 1.45           29.84 ± 1.33         29.87 ± 1.36         0.999
   placebo           28.98 ± 0.89                                                29.16 ± 0.90           29.05 ± 0.94         29.04 ± 0.78         \>0.05
  MCHC (g·dL^-1^)                                                                                                                                 
   α-lipoic acid     33.18 ± 0.89                                                33.50 ± 1.00           33.29 ± 0.93         33.18 ± 0.94         0.997
   placebo           33.36 ± 0.36                                                33.73 ± 0.23           33.39 ± 0.53         33.36 ± 0.52         \>0.05

Note: The first P-value for each variable is the group x time interaction effect, and the second is the time effect.

Abbreviations: EPO -- erythropoietin, HB -- haemoglobin, RBC -- red blood cells, HCT -- haematocrit, RET -- reticulocytes, MCV -- mean cell volume, MCH -- mean corpuscular haemoglobin, MCHC -- mean corpuscular haemoglobin concentration

Creatine kinase {#S20014}
---------------

Total initial CK activity was slightly lower in the α-lipoic acid group than in placebo but the difference was not statistically significant. Interestingly, in the group treated with α-lipoic acid, CK activity was significantly lower than in placebo during recovery. The CK peak values were reached at 24 h after the cessation of exercise in both groups (481 ± 103 IU · L^-1^ vs. 732 ± 207 IU · L^-1^) and then gradually fell until 48 h post-exercise (434 ± 86 IU · L^-1^ vs. 568 ± 120 IU · L^-1^) ([Figure 3](#F0003){ref-type="fig"}).

![CHANGES IN TOTAL SERUM CREATINE KINASE (CK)\
Note: \*P \< 0.05, \*P \< 0.01 and \*\*\*P \< 0.001 significantly different compared with pre-exercise level. CK activity was significantly different (P \< 0.05) in α-lipoic acid compared with placebo at 24 h post-exercise.](JBS-31-1111435-g003){#F0003}

DISCUSSION {#S0004}
==========

Many studies have concluded that intracellular RN/OS production is a required signal for the exercise adaptation that occurs in the cardiovascular system and skeletal muscles in response to repeated exercise \[[@CIT0029]\]. Our results have shown that running eccentric exercise elevates NO and H~2~O~2~ generation. However, a rise in H~2~O~2~ occurred before changes in NO level. Lima-Cabello et al. \[[@CIT0022]\] demonstrated that muscle contractions modulate the NO synthesis via NO synthases (NOS) through the signalling pathways are controlled by H~2~O~2~-activated nuclear factor κB. Therefore antioxidants affecting H~2~O~2~ generation can indirectly modulate NO release.

The applied high α-lipoic acid dose increased H~2~O~2~ but reduced NO concentration. This could be caused by inhibition of an inducible isoform of NOS expression by α-lipoic acid through destabilization of its mRNA, resulting in decreased NO production \[[@CIT0035]\]. The excess NO reacts with the superoxide anion to produce peroxynitrite (ONOO^-^), which can induce mitochondrial dysfunction, lipid and protein oxidation \[[@CIT0028]\]. α-Lipoic acid shows the ability to react directly with ONOO^-^ and to reduce nitro-oxidative stress \[[@CIT0033]\]. It has been demonstrated to be effective in preventing various diseases in which RN/OS have been implicated, such as cardiovascular diseases, diabetes, hypertension and radiation injury \[[@CIT0030]\].

The measure of RN/OS markers such as 8-iso, LPO and PC can offer an empirical view on the complex process of peroxidation and carbonylation followed by diseases, aging or exhaustive exercise \[[@CIT0029]\]. Our study confirmed the effectiveness of α-lipoic acid in the protection of lipids and proteins against over-activity of RN/OS. The used markers of RN/OS activity decreased following high α-lipoic acid intake, especially lipid peroxidation products 8-iso and LPO. Previously, a few researchers reported a positive effect of α-lipoic acid on lipid composition in various tissues. Manda et al. \[[@CIT0023]\] observed a significant decrease in peroxidation products in X-irradiated mouse cerebellar tissue following treatment with α-lipoic acid. Baydas et al. \[[@CIT0001]\] demonstrated an α-lipoic acid-mediated protective effect against lipid peroxidation in the glial cells of diabetic rats.

NO and H~2~O~2~ are involved in signal transduction pathways. H~2~O~2~ was previously indicated as part of the O~2~-sensing mechanism stabilizing transcription factor HIF-1 and regulating EPO expression, and as a signal for cell growth and differentiation of erythroid progenitor cells \[[@CIT0017]\]. The next observations indicated the key role of NO in HIF-1α stabilization \[[@CIT0006]\]. According to Haase \[[@CIT0013]\], during hypoxia transcriptional activity of HIF-1 is more dependent on changes in H~2~O~2~, whereas during non-hypoxic conditions HIF-1 activity is related to NO, pro-inflammatory cytokines IL-β and TNFα, as well as growth factors including epidermal growth factor, insulin, and insulin-like growth factor I. We observed that α-lipoic acid elevates H~2~O~2~ and EPO, and reduces NO level at rest. This means that H~2~O~2~ may be more involved in EPO release than NO. Although EPO did not separately correlate with H~2~O~2~ and NO, it highly correlated with the ratio of NO to H~2~O~2~. We suppose that EPO synthesis may require changes in levels of both molecules. It was recently reported that HIF-1 transcriptional activity and EPO expression are achieved through two parallel pathways: a decrease in O~2~-dependent hydroxylation of HIF-1 and S-nitrosylation of HIF-1 pathway components \[[@CIT0016]\].

α-Lipoic acid can effect muscle regeneration through regulation of RN/OS and EPO production. Endogenously produced EPO and/or expression of the EPO receptor gives rise to autocrine and paracrine signalling in skeletal muscles particularly during hypoxia and injury conditions. In the last decade, numerous studies have confirmed that apart from its haematopoietic effect, EPO is active in muscle, neural, endothelial, cardiovascular and renal tissues \[[@CIT0021], [@CIT0025]\]. In skeletal muscles, EPO stimulates proliferation of myoblasts and has a potential role in muscle mass maintenance. Furthermore, EPO directly contributes to increased PGC-1α activity and affects skeletal muscle development and the balance of slow and fast-twitch fibre determination \[[@CIT0034]\]. High α-lipoic acid intake increased EPO concentration and reduced total CK activity at 24 h and 48 h after exercise. A significant positive correlation was observed between CK and EPO. Mille-Hamard et al. \[[@CIT0025]\] reported that EPO exerts both direct and indirect muscle-protecting effects during intense exercise. However, the authors stressed that the signalling pathway involved in protective effects of EPO remains to be described in detail.

The increase in serum CK activity is normally related to intense physical activity and strongly correlates with the type and the amount of exercise. It depends on the degree of injury of the skeletal muscle cell structure. Therefore, CK is widely used in monitoring of training load, physical efficacy and overtraining in athletes. The skeletal muscles performing eccentric exercise are particularly exposed to damage as the result of disruption of sarcomeres, leading to intensified CK efflux into the extracellular space and markedly higher CK activity in the blood \[[@CIT0024]\]. The study revealed differences in CK response to eccentric exercise depending on α-lipoic acid intake. Participants supplemented with α-lipoic acid had significantly lower CK activity than control individuals taking placebo. This was in line with earlier observations of Kim and Chae \[[@CIT0020]\], who demonstrated significantly lower CK values in rats supplemented with α-lipoic acid for 6 weeks irrespectively of exercise. One of the postulated reasons of lower muscle injury could be membrane protective effects of α-lipoic acid against exercise-induced oxidative damage as the result of attenuation of lipid peroxidation and membrane permeability \[[@CIT0012]\]. Although the CK activity shows remarkable intra- and inter-individual variations under exercise condition, some authors have defined a blurred boundary between harmless and damaging physical activities at the level of about 300-500 IU · mL^-1^ of the enzyme activity \[[@CIT0003]\]. α-Lipoic acid intake significantly reduced excessive CK efflux during exercise performance thus suggesting its muscle protective capabilities in the study. This highly beneficial effect could be a matter of particular interest for the future in preventing an extremely high CK response to exercise rhabdomyolysis in athletes \[[@CIT0004], [@CIT0019]\] and statin-induced rhabdomyolysis in a substantial proportion of patients treated for dyslipidaemia \[[@CIT0005], [@CIT0032]\].

CONCLUSIONS {#S0005}
===========

In conclusion, the current results confirm the antioxidative properties of α-lipoic acid, and indicate a possible use of α-lipoic acid to improve EPO production and skeletal muscle regeneration through changes in the RN/OS ratio at rest and after exercise.
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